A novel nuclear form of estradiol receptor in MCF-7 human breast cancer cells.

Nuclear estrogen receptor from MCF-7 cells undergoes a time-dependent, hormone-inducible transformation to a form that is less extractable from nuclei and less exchangeable with ligand. This receptor-modifying, intranuclear event is independent of receptor loss (processing) and appears associated with hormone responsiveness (progesterone-receptor induction) in these cells. The magnitude of receptor loss, however, is variable and apparently not a prerequisite for hormone action to induce progesterone receptor.

Transfection of v-rasH DNA into MCF-7 human breast cancer cells bypasses dependence on estrogen for tumorigenicity.

The natural history of estrogen-responsive breast cancers often involves a phenotypic change to an estrogen-unresponsive, more aggressive tumor. The human breast cancer cell line, MCF-7, which requires estradiol for tumor formation in vivo and shows growth stimulation in response to estradiol in vitro, is a model for hormone-responsive tumors. The v-rasH onc gene was transfected into MCF-7 cells. The cloned MCF-7ras transfectants, which expressed the v-rasH messenger RNA and v-rasH p21 protein (21,000 daltons), were characterized. In contrast to the parental cell line, MCF-7ras cells no longer responded to exogenous estrogen in culture and their growth was minimally inhibited by exogenous antiestrogens. When tested in the nude mouse, the MCF-7ras cells were fully tumorigenic in the absence of estrogen supplementation. Thus, cells acquiring an activated onc gene can bypass the hormonal regulatory signals that trigger the neoplastic growth of a human breast cancer cell line.

Effect of v-rasH oncogene transfection on estrogen-independent tumorigenicity of estrogen-dependent human breast cancer cells.

Spontaneous or therapeutically induced progression of hormone-dependent human breast cancer to a form not amenable to endocrine treatment has been frequently recorded in clinical settings. In an experimental model system, we have changed the estrogen-dependent tumorigenicity of a human breast cancer cell line, MCF-7, to an independent state by stably introducing a model oncogene, v-rasH, into this cell line by means of DNA transfection. We now show that the oncogene-transfected hormone-independent MCF-7 cells may secrete diffusible tumorigenic factors that not only support their own tumor growth in vivo, but are also humorally active in partially triggering the tumor growth of wild type previously nontumorigenic MCF-7 cells, even when the wild type cells are implanted at a distant anatomical site in the same animal. Estrogen-independent tumor formation by MCF-7 cells was also induced in 50% of animals given injection by continuous administration of conditioned media from MCF-7-ras cells. However, the wild type tumors had limited tumor growth. Tumors were verified as adenocarcinomas and by Southern blotting were shown to be derived from the cells injected. In an in vitro coculture assay, a 5- to 7-fold enhancement in anchorage-independent growth of MCF-7 cells was observed in the presence of MCF-7-ras feeder cell layer. These data suggest that v-rasH-induced estrogen-independent tumorigenicity of human breast cancer cells occurs by secretion of mitogens which may function in an endocrine manner.

Relationship between the expression of estrogen-regulated genes and estrogen-stimulated proliferation of MCF-7 mammary tumor cells.

The growth of MCF-7 cells was arrested by 24 h of isoleucine deprivation. Following replenishment of the medium, the incorporation of uridine and thymidine into trichloroacetic acid-precipitable material began to increase slowly and gradually rose to the level of cycling cells. The addition of 5 X 10(-9) M estradiol to growth-arrested cells dramatically shortened the time of onset of macromolecular synthesis and increased the overall amount of precursor incorporation 2- to 4-fold over the level obtained by arrested control cells. The increase in uridine incorporation preceded the increase in thymidine incorporation by 6 h. Inhibition of protein synthesis with cycloheximide blocked the recovery of macromolecular synthesis in both control and estrogen-treated cells. Actinomycin D was ineffective in blocking the estrogen-stimulated recovery of macromolecular synthesis at concentrations known to inhibit pre-rRNA synthesis (10(-8) M). At higher concentrations, uridine and thymidine incorporation were inhibited in a dose-dependent manner. Inhibition of RNA polymerase II activity with alpha-amanitin similarly blocked both the recovery of the cells from isoleucine starvation and the potentiation of this by estradiol. Dihydrofolate reductase and thymidine kinase activities are both stimulated by estradiol in MCF-7 cells. In cycling cells, estrogen stimulates a 2-fold increase in their messenger RNAs (mRNAs) within 24 h. The level of dihydrofolate reductase mRNA is unaffected by isoleucine starvation, and estrogen caused no change in dihydrofolate reductase mRNA levels over a 24-h period following reversal of growth arrest. Similar results were observed for the 600-nucleotide pS2 mRNA that has been identified as an estrogen-induced RNA in MCF-7 cells. In contrast, thymidine kinase mRNA was found to be increased by estrogen at 24 h, but not at 12 h, following reversal of growth arrest. This increase correlates with increases in thymidine, but not uridine incorporation. These data indicate that the estrogen-stimulated increase in thymidine incorporation following release from growth arrest is dependent on new RNA synthesis. However, the hormone did not increase the levels of three estrogen-regulated mRNAs coordinately with the increases observed in uridine incorporation.

Expression of transforming growth factor alpha in normal human adult kidney and enhanced expression of transforming growth factors alpha and beta 1 in renal cell carcinoma.

Normal kidney and renal cell carcinoma tissues from ten patients were studied for mRNA and DNA for both transforming growth factors alpha and beta 1. Northern and Southern hybridizations were conducted on samples extracted from the solid tumor and surrounding normal tissues and two tumor-derived cell lines. Low levels of constitutive expression of TGF-alpha mRNA were detected in all normal kidney tissues; six of the ten patients, however, demonstrated an increased (2- to 8-fold) expression of TGF-alpha in the tumor versus normal kidney as determined by densitometry of RNA blots. All ten patients had elevated mRNA levels for TGF-beta 1 in the tumor (2.5-to 22-fold increase) relative to normal kidney. Two tumor-derived cell lines also expressed TGF-alpha and TGF-beta 1 mRNA. Southern blot hybridization of the DNA extracted from the normal tumor pairs revealed no gene amplification or gross rearrangement for either the TGF-alpha or TGF-beta 1 genes. These results demonstrate the expected constitutive expression of TGF-beta 1 by normal kidney; however, the constitutive expression of TGF-alpha by Northern blot analysis in normal adult human kidney is previously unreported. Enhanced expression of TGF-alpha and TGF-beta 1 mRNA in solid tumor may be related to the development of renal cell carcinoma.

Cytokine regulation of tumor necrosis factor-alpha and -beta (lymphotoxin)-messenger RNA expression in human peripheral blood mononuclear cells.

The immune response at the molecular level is characterized by a carefully coordinated interplay of both cytokine production and receptor induction. The regulation of these molecules including the closely related tumor necrosis factors alpha (TNF) and beta (lymphotoxin, LT) is still incompletely understood. We have examined the effects of various cytokines on the expression of TNF and LT mRNA in human peripheral blood mononuclear cells (PBMC). Northern blot analysis with total cellular RNA from mixed populations of PBMC revealed that genes coding for TNF and LT were not spontaneously expressed. Treatment of PBMC with recombinant interleukin (IL)-2 resulted in a high level expression of TNF and LT mRNA. Whereas IL-1 beta was equally effective as IL-2 in inducing both TNF and LT mRNA, granulocyte-macrophage colony-stimulating factor selectively induced only TNF mRNA. Both TNF and LT mRNA were minimally induced by IL-1 alpha, IL-3, interferon (IFN)-alpha, or IFN-gamma. Similarly TNF alone had little effect on induction of TNF and LT mRNA. In conjunction with IL-2, cytokines such as IFN-alpha, IFN-gamma, or TNF did not interfere with IL-2 induction of TNF and LT mRNA. Interestingly, IL-4 in combination with IL-2 inhibited the IL-2-driven induction of TNF and LT mRNA. This inhibitory effect of IL-4 was also observed at the level of TNF and LT protein secretion. Furthermore, IL-4 was also inhibitory of IL-2-mediated induction of Tac mRNA in PBMC. These results extend the interrelationship of cytokine regulation of TNF and LT expression. In particular, they reveal the previously unrecognized function of IL-4 in antagonizing the IL-2 induction of TNF, LT, and Tac mRNA in PBMC.

[125I]17-alpha-iodovinyl 11-beta-methoxyestradiol interaction in vivo with estrogen receptors in hormone-independent MCF-7 human breast cancer transfected with the v-rasH oncogene.

[125I]17-alpha-Iodovinyl 11-beta-methoxyestradiol [( 125I]MIVE2) has been evaluated as a potential radiotracer for the diagnostic imaging of estrogen receptor (ER)-positive human breast cancer. In vivo distribution experiments with athymic ovariectomized nude mice bearing human breast tumors revealed an apparent correlation between uptake of 125I-labeled compound and estrogen receptor concentration in the tumors. At 4 h after i.v. injection of [125I]MIVE2, HS578T (ER negative), ZR75-B (intermediate ER), and MCF-7ras (high ER) tumors accumulated 0.320 +/- 0.186, 0.679 +/- 0.467, and 2.6163 +/- 1.0121% injected dose/g, respectively. With coinjection of unlabeled 17-beta-estradiol, levels of radioactivity in MCF-7ras tumors were decreased to 0.4859 +/- 0.1424% injected dose/g, indicating a receptor-mediated process. Peak activity of radioligand in MCF-7ras tumors and uteri was observed at 2 h and was retained for the 8-h time course. Blood and nontarget tissue, such as muscle, revealed a rapid clearance of 125I-labeled compound by 8 h. Eight hours after injection, uterus and tumor-to-blood ratios were calculated to be 225 and 21, respectively. Also, MCF-7ras tumors were shown to accumulate 6.5-fold more radioactivity than muscle. These data suggest that [125I]MIVE2 has the capability of interacting specifically and with high affinity with estrogen receptors in human breast tumors in nude mice and may possibly be used for imaging receptor-positive tumors in breast cancer patients with very low serum estrogen levels. Selective uptake of compound in MCF-7ras tumors emphasizes the usefulness of an estrogen receptor-positive tumor model which has a unique ability to grow in a host system without circulating estrogens.

Interleukin-1 alpha and tumor necrosis factor-alpha (TNF alpha) inhibit growth and induce TNF messenger RNA in MCF-7 human breast cancer cells.

We studied the effects of interleukin-1 alpha (IL-1) and tumor necrosis factor-alpha (TNF), alone and in combination, on MCF-7 breast cancer cells to determine whether these cytokines alter cell growth, TNF gene expression, and TNF secretion. We found that IL-1 alone and TNF alone inhibited cell growth in a dose-dependent manner. Each cytokine arrested growth in the G0/G1 phase of the cell cycle, with maximum growth inhibition at 1000 U/ml (P less than 0.05) and 100 U/ml (P less than 0.01), respectively. However, the combination of these two cytokines did not result in greater growth inhibition or a greater percentage of cells arrested in the G0/G1 phase of the cell cycle compared with each cytokine alone. We examined the effect of exogenous IL-1 and TNF on TNF gene expression by Northern blot analysis. In the absence of any cytokine, these cells do not express TNF mRNA. Exposure to IL-1 (1000 U/ml) induced TNF mRNA at 3 h; however, mRNA levels diminished thereafter to barely detectable levels by 24 h. Exposure to TNF (1000 U/ml) also induced TNF mRNA at 3 h, but in contrast to IL-1, the level of enhanced expression persisted at these levels through 72 h of exposure. Secretion of TNF by these cells is induced by exogenous TNF, but not by IL-1. IL-1 and TNF in combination do not produce greater inhibition of growth, greater amounts of TNF mRNA at 3 h, or greater secretion of TNF than that produced by TNF alone.(ABSTRACT TRUNCATED AT 250 WORDS)

Selection of gene-marked tumor infiltrating lymphocytes from post-treatment biopsies: a case study.

Patients with malignant melanoma have been treated with interleukin-2 (IL-2) and tumor-infiltrating lymphocytes (TIL) marked by retroviral gene transduction. The retroviral vector contained a gene coding for the bacterial enzyme neomycin phosphotransferase, such that transduced TIL expressing the enzyme could survive otherwise toxic concentrations of the neomycin analogue G418. For 1 patient, who exhibited a complete regression of cancer after treatment with TIL, lymphocytes from post-treatment blood and tumor biopsies were cultured in IL-2, and transduced TIL were recovered by G418 selection. Analysis of T-cell receptor heterogeneity indicated that the transduced TIL recovered from the tumor biopsy were different from TIL that were kept strictly in vitro and selected in G418. The selection process required weeks in culture, during which time control cultures changed radically in subset composition, so there was also a simultaneous selection for long-term in vitro growth advantage. It cannot be certain that the TIL subsets preferentially recovered from the tumor biopsy corresponded to those that mediated complete elimination of tumor in this patient.

Nuclear progestin receptors in human uterus.

The characteristics and transfer of human uterine progestin receptors from cytosol to nucleus were studied in a cell-free system using [3H]progesterone ([3H]P), [3H]norethindrone ([3H]NET), and [3H]norethindrone acetate ([3H]NETA) as progestin receptor tags. Nuclear receptor binding was observed only in the presence of uterine cytosol. Various prior treatments of uterine cytosol, including warming to 20 C, increasing the salt concentration to 150 mM KCl, or dilution of the cytosol protein concentration to 3 mg/ml, increased the affinity of the receptor for the cell nucleus and thus, facilitated more translocation. However, there was no detectable difference in the receptor sedimentation value after activation. The binding of salt-extractable (400 mM KCl) nuclear sites to [3H]P, [3H]NET, and [3H]NETA was characterized by distinct commonality in their physiochemical properties, as indexed by their coelution during gel chromatography (mol wt, 72,000), their similar sedimentation rates (4.2S), and their similar isoelectric profiles (isoelectric pH 5.3--5.6). The concentrations of specific binding sites were similar for the different 3H-labeled progestins used. However, in general, the number of binding sites was higher (3780--4480 molecules/cell) in proliferative phase tissues and significantly lower (1790--1920 molecules/cell) in secretory phase tissues. Furthermore, nuclear binding was progestin specific and of high affinity (Kd of NET, similar to or approximately 0.7--0.8 nM; Kd of P, similar to or approximately 0.9--1.2 nM; Kd of NETA, similar to or approximately 6.7--7.1 nM). Despite the similarities in the molecular properties, the nuclear bindings of NET and NETA could be distinguished from that of P by their lower dissociation rates (t 1/2 of NET, similar to or approximately 6.3 h; t 1/2 of NETA, similar to or approximately 5.5 h; t 1/2 of P, similar to or approximately 1.2 h). Moreover, NET and NETA, unlike P, did not bind to corticosteroid-binding globulin. These observations indicate that the various progestins mediate their action via a common receptor, which translocates from cytosol to nucleus. Further, because of the distinct advantages, NET could be conveniently used as a receptor tag to evaluate the progestin receptor.

Kinetic alterations in estrogen receptors associated with estrogen receptor processing in human breast cancer cells.

After nuclear translocation of estrogen receptors in MCF-7 human breast cancer cells, a processing takes place resulting in a 30-70% decline in the number of estradiol-binding sites measured in nuclear extracts. We have investigated the mechanism of estrogen receptor processing and obtained evidence that multiple events are involved. We confirm, as others have shown previously, that processing involves a decrease in the amount of estradiol binding in MCF-7 cells. In addition, evidence is provided for the generation of a rapidly dissociating population of estradiol-binding sites as an early event in processing. There is a single, slowly dissociating population of estrogen binding sites when MCF-7 cells are exposed to estradiol in the presence of actinomycin D, an inhibitor of receptor processing. One hour after the addition of sufficient estradiol to induce receptor processing, an additional, more rapidly dissociating population of estrogen binding sites is detected. When cells are exposed to estradiol and ethidium bromide, a drug which shares many actions with actinomycin D, but does not inhibit receptor processing, the rapidly dissociating population of estradiol-binding sites is again observed. Significantly, the loss of estradiol-binding sites from MCF-7 cells associated with processing between 1 and 6 h of estradiol exposure, occurs exclusively from the rapidly dissociating population of sites. Whole cell equilibrium-binding assays were performed with MCF-7 cells after 30 min or 5 h of estradiol exposure to determine whether the detected changes in estradiol dissociation reflected affinity changes in a subpopulation of estrogen-binding sites. Although the number of sites detected per cell varied with the assay method employed, binding to a single saturable class of higher affinity sites is always observed. High affinity estradiol-binding sites were reduced by 45% after a 5-h incubation with estradiol in both assay methods. The loss of estradiol binding during processing may therefore be explained by the conversion of certain high affinity estrogen receptors to a rapidly dissociating form which then fails to rebind hormone, or undergoes subsequent reactions that destroy hormone binding activity. Additionally, after 6 h of exposure to estradiol, the remaining receptor-bound estradiol dissociates from intact cells with a rate increased by 50% over that seen from the slow dissociating receptors present at 1 h.(ABSTRACT TRUNCATED AT 400 WORDS)

A novel TC deletion resulting in Pro(260)-->Stop in the human LCAT gene is associated with a dominant effect on HDL-cholesterol.

Human lecithin:cholesterol acyltransferase (LCAT) plays a key role in the biogenesis of circulating high-density lipoprotein-cholesterol (HDL-C) and reverse cholesterol efflux. We investigated the molecular defect in the LCAT gene in a family with low levels of HDL-C. The proband, a 53-year-old woman from Oklahoma City, had a HDL-C level of 0.21 mmol/l. The LCAT activity in the proband was 5 nmol/ml/h and cholesterol esterification rate was 54.2 nmol/ml/h, consistent with LCAT deficiency. Analysis of polymerase chain reaction (PCR) amplified subgenomic fragments of LCAT DNA on polyacrylamide gels revealed heteroduplex bands in the proband and three other affected individuals in exon 6. DNA sequence analyses of the proband's LCAT gene identified a 2 base pair deletion (TC) (base pairs 4544-4545, corresponding to amino acid 255) in the heteroduplex allele, thereby converting Pro(260) to a premature stop codon and a predicted truncated protein of 260 amino acids. This is approximately 60% of the length of the normal translated protein. The heterozygous individuals also revealed significant reduction in apolipoprotein A-1 levels compared with the unaffected family members (n=4). The marked reduction in HDL-C in the proband and sibling suggests a dominant effect of this mutation on HDL-C levels. Furthermore, because the deletion results in a heterozygous allele that can be detected by a simple PCR reaction and polyacrylamide gel-size fractionation, it may be possible to rapidly screen susceptible individuals for the presence of this mutation.

Progestin receptors in human uterine cytosol.

Progestin(norethindrone and norethindrone acetate)-binding protein, exhibiting characteristics similar to uterine progesterone receptor, has been identified in human uterine cytosol. The progestin receptor was characterized by sedimentation coefficient, 4.2 S; Stokes radius, 39 A; frictional ratio, 1.29; isoelectric pH, 4.6; molecular radius, 2.7 nm; and molecular weight in the range 67 000--74 000. The ammonium-sulfate-precipitated progestin-receptor complex was eluted from a DEAE-cellulose column at 0.18 M KCl. The progestin binding was saturable and stereospecific. The sequential variation in receptor concentration (early proliferative, 3800--4300 sites/cell; late proliferative, 9500--11 200 sites/cell; early secretory, 4900--6200 sites/cell; late secretory, 1800--2300 sites/cell) was in conformity for progesterone and the progestins, when concurrently measured. Oral administration of norethindrone significantly reduced the cytoplasmic and nuclear receptor concentration for estradiol and progesterone. A significant observation was that the progestins stabilized the receptor by forming a slowly dissociating complex with a t 1/2 approximately 110--130 min as compared with the progesterone-receptor complex dissociating with t 1/2 approximately 41 min. Thus, the uterine progestin receptor recognizes progestins in general, although with a varying degree of affinity, and the altered rate constants could be of putative importance in determining the biological potency of the progestins.

Gene expression in normal and doxorubicin-impaired wounds: importance of transforming growth factor-beta.

The function of transforming growth factor-beta (TGF-beta) in vivo remains unknown despite the fact that it has been identified in numerous biologic processes involving the regulation of cell growth including tissue repair. Doxorubicin is a potent antitumor drug that has been shown to have detrimental effects on wound healing. With specific complementary DNA probes for TFG-beta and type 1 collagen, RNA from wounds of rats treated with saline solution and doxorubicin was analyzed for the expression of each gene at different times after wounding. In a second study, either 2 micrograms exogenous TGF-beta or vehicle was added to wounds of rats treated with doxorubicin, and wound RNA was analyzed in a similar manner. In wounds from rats treated with saline solution, messenger RNA (mRNA) for TGF-beta peaks on day 7 after wounding and is also elevated on days 3 and 10; mRNA for collagen is elevated on days 7 and 10. Doxorubicin decreases mRNA for TGF-beta and collagen on each day. Topical application of TGF-beta to wounds of rats treated with doxorubicin increases collagen mRNA levels to normal or supranormal levels. This study suggests that the impaired healing induced by doxorubicin may be a result of decreased gene expression for TGF-beta and that topical replacement of this growth factor may correct the defect.

Guillain-Barre syndrome. Pattern of muscle weakness.

OBJECTIVE: The objective of this study was to determine the pattern of muscle weakness in patients with Guillain-Barre Syndrome. METHODS: In a cross-sectional study, 50 Iraqi patients aged one to 60 years diagnosed with Guillain-Barre Syndrome according to Asbury criteria, admitted in 5 Neurological Centers in Baghdad, Iraq between October 1997 and October 1999, were studied for pattern of muscle weakness by clinical evaluation of power using scale from 0-5. RESULTS: In 80% of patients, muscle weakness started in lower limbs while at presentation 4 limb weakness was the most frequent (96%). It was found that the upper extremity weakness was mainly distal in 73% of patients, while lower extremity weakness was mainly proximal in 68%. Weakness in extremities associated with cranial nerve involvement occurred in 72% of patients. Trunk muscles were involved in 34%. Various modes of spread of muscle weakness were seen in this study but the ascending variety was the most common occurring in 78% of patients and it was characterized by upward spread, however, contiguous parts of the body were not always successively involved. CONCLUSION: Upper extremity weakness was mainly distal while lower extremity weakness was mainly proximal and there is predilection for trunk muscle involvement that is quite unusual in other types of polyneuropathy. Therefore, all patients with suspected Guillain-Barre Syndrome should be examined carefully for pattern of muscle weakness in extremities, which may be helpful in differential diagnosis especially in early stages of the disease.

Cerebral palsy in adults consequences of non progressive pathology.

OBJECTIVE: Cerebral palsy (CP) is a disability that affects individuals throughout their lifespan. This study was conducted to evaluate the clinical status of adults with cerebral palsy. METHODS: A cross-sectional study was carried out during the period of February 2001 to June 2002, in Baghdad, Iraq. Fifty young adult men with cerebral palsy were evaluated by reviewing their medical records and present clinical status. RESULTS: Antenatal maternal medical problems were recorded in 17 (34%) cases. Kernicterus was the most common possible cause occurring in 14 (28%) cases. Spastic hemiplegia was reported in 16 (32%) patients. Various forms of combinations occured in 14 (28%) cases. Of the secondary disabilities, musculoskeletal disorders were the most common (60%), followed by epilepsy (42%), mental retardation (40%), speech disorders (30%), bladder dysfunction (4%) and visual impairment (2%). Relationships between musculoskeletal deformities and the development of mental retardation were statistically significant (P value 0.0001) . CONCLUSION: Adults with CP are at risk of many highly preventable secondary conditions that cause loss of function and deterioration of quality of life.

Estrogen and oncogene mediated growth regulation of human breast cancer cells.

The mechanism of growth control in estrogen-dependent and -independent human breast cancer is not completely understood. We have used both hormonally responsive and unresponsive breast cancer cells in culture to study the role of estrogens, oncogenes, and growth factors in their malignant transformation. MCF-7, an estrogen-receptor containing cell line, requires estradiol for tumor formation in vivo and is growth stimulated by estradiol and growth inhibited by antiestrogens in vitro. The growth regulation of MCF-7 cells by estrogens and antiestrogens may be linked to changes in several growth-related enzymes and polypeptide growth factors. Growth-acting polypeptides that are estradiol-inducible include IGF-I, TGF-alpha, and PDGF. Induction of at least two growth-related enzymes, thymidine kinase and dihydrofolate reductase is by transcriptional regulation of their mRNAs. To understand the natural progression of human breast cancer, we have experimentally constructed a hormone-independent fully tumorigenic cell line from the non-tumorigenic MCF-7 cells by introduction of an activated oncogene, v-rasH, into these cells by DNA-mediated gene transfer. Acquisition of the activated ras gene confers hormone autonomy on the previously hormone-dependent tumorigenicity and results in upregulation in secretion of some of the growth factors in amounts compared to estradiol stimulation. The transfected cells also become refractory to growth regulation by estradiol and antiestrogens in culture, although estrogen responses persist. Hormone-independent breast cancer cells in culture show high constitutive growth factor secretion. Direct infusion of some of the authentic growth factors and medium conditioned by estrogen-independent cells into athymic ovariectomized mice suggests a direct involvement of some of the polypeptides in the in vivo progression of tumors by these cells. Thus, aberrant production of growth factors, triggered either by activated oncogenes and estrogen stimulation in hormone-dependent cells, or by increased constitutive production in hormone-independent cells may in an autocrine, paracrine, or endocrine manner be associated with neoplastic growth of breast cancer.

Effects of transforming growth factor-beta on human lymphokine-activated killer cell precursors. Autocrine inhibition of cellular proliferation and differentiation to immune killer cells.

With subpopulations of human lymphoid cells that were enriched for lymphokine-activated killer (LAK) cell precursors, studies were performed to examine the effects of transforming growth factor-beta (TGF-beta) on their IL-2-dependent growth and differentiation to killer cells. The majority of the LAK precursor cells appeared to reside in nonadherent, non-T, and non-B lymphocyte populations that expressed CD11 and CD16 Ag. These cells were induced to proliferate and become LAK cells by high concentrations of rIL-2 alone in the apparent absence of any prior activation with mitogen or Ag. The partially purified lymphocyte subpopulations generated varying but several-fold greater levels of LAK killing on a per cell basis than did unfractionated lymphocytes. The exogenous addition of TGF-beta to the LAK precursor cultures, markedly inhibited IL-2-stimulated growth as well as the development of LAK activity in a dose-dependent manner. The antimitotic effect of TGF-beta was reversible; inhibition of proliferation could be largely restored by increasing the concentration of IL-2 in culture. In contrast, TGF-beta inhibition of cytotoxicity was relatively independent of the concentration of IL-2. Further, LAK precursors constitutively expressed TGF-beta mRNA and high affinity receptor for TGF-beta. Activation of LAK precursors with IL-2 alone, resulted in a three- to fivefold up-regulation of intracellular TGF-beta mRNA and TGF-beta biologic activity secreted in the culture media. Furthermore, Northern blotting revealed that the resting LAK precursors did not express the Tac-mRNA. Receptor binding studies with 125I-IL-2 suggested the presence of a single class of IL-2R with an apparent Kd of intermediate range (beta-chain of IL-2R) on the unstimulated cells. Stimulation with high concentrations of Il-2 induced Tac-mRNA (both the 3.5- and 1.5-kb transcripts) and resulted in the expression of high affinity IL-2R (Kd approximately 10(-11) M) on these cells. Suppression of IL-2-dependent responses by TGF-beta was accompanied by a selective down-regulation of the 1.5-kb Tac-mRNA as well as by reduction in high affinity IL-2R. The results suggest a negative autocrine control of TGF-beta on IL-2-dependent growth and differentiation of human LAK cells, possibly related to regulate the killer activation function.